Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Colorectal Neoplasms 8Carcinoma, Hepatocellular 8Stomach Neoplasms 2Neoplasms 2Liver Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Liver Diseases 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 29Carboplatin 10Surveys and Questionnaires 9Paclitaxel 9Trastuzumab 8Nivolumab 8Cisplatin 8Taxes 7Gemcitabine 7Bevacizumab 6Specimen Handling 5Oxaliplatin 5Irinotecan 5Fluorouracil 5Cetuximab 5Biopsy 5spartalizumab 4Leucovorin 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4tisotumab vedotin 3fludarabine 3durvalumab 3atezolizumab 3aldesleukin 3X-Rays 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Interviews as Topic 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Axitinib × Gastrointestinal × Clear all
NCT04458259 2026-06-04

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Pfizer

Phase 1 Terminated
88 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡